CUHK-Led Trial Signals Long-Term Control for ALK-Positive Lung Cancer with Lorlatinib
A Hong Kong co-led global trial reported by SCMP found 55% of previously untreated advanced ALK-positive NSCLC patients on lorlatinib had no disease progression at seven years, versus 3% on crizotinib. The findings support a strategic shift toward managing certain advanced cancers as chronic conditions, with implications for diagnostics, reimbursement, and long-term care capacity.